49 results about "VEGF binding" patented technology

Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.

Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a Dll4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and Dll4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Disclosed are novel peptides inhibitory of the activity of vascular endothelial growth factor (VEGF) and their use in the treatment of angiogenesis-related diseases, including cancer. A combinatorial library of peptides consisting of six amino acid residues were chemically synthesize and, from the library, specific amino acid residues for each amino acid position were screened by comparing their inhibitory activity against VEGF binding to the cell surface receptor. The novel peptide sequences thus obtained bind to VEGF and block the binding of VEGF to its receptors present on the surface of vascular endothelial cells, thereby inhibiting the hormonal activity of VEGF. The peptides inhibit the angiogenesis induced by VEGF and human cancer cells. Also, the peptides inhibit growth and metastasis of human cancer cells transplanted to mice. Thus, the peptides can be used to treat angiogenesis-related diseases, including cancer, diabetic retinopathy, rheumatoid arthritis, etc.

The invention discloses a preparation method of artificial alveoli. The method comprises the following steps: firstly, preparing gelatin micro-spheres with uniform diameters from a gelatin aqueous solution through a microfluidic device, obtaining gelatin brackets which are regularly arranged through a self-assembly method, heating the gelatin brackets to be closely arranged, then filling a PU solution, performing freeze drying to remove the solvent, and removing a gelatin template by a water bath method to obtain a three-dimensional porous PU bracket with an inverse opal structure; then, performing ammonia plasma treatment on the PU bracket to graft the amino group, connecting heparin to the amino group through EDC / NHS, then adding VEGF, and combining the VEGF to the heparin; and finally,rotationally inoculating MRC-5 cells to the VEGF-modified PU bracket, proportionally inoculating mixed cell suspensions of HUVECs and NL20 cells, and performing co-culture to obtain tissue engineeringartificial alveoli. The diameters of the prepared artificial alveoli can be effectively regulated and controlled to be about 300 microns by regulating and controlling the concentration of the gelatinsolution and polyurethane, the flow rate and the passage diameter of a water phase and an organic phase as well as the self-assembly temperature and time.

Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and / or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.